Vascular Discovery 2019: From Genes to Medicine (Formerly ATVB:PVD): May 14-16, 2019; Boston, MA. Final program here. Resverlogix has two presentations: #407 and #671:  

Wednesday May 15: 407 - Apabetalone (RVX-208) Inhibits Key Pro-Atherogenic Mediators and Pathways in Diabetes and Inflammatory Conditions; in vitro and in Patients. Abstract currently embargoed but will be available here.

Thursday May 16: 671 - Hepatic Expression of C-Reactive Protein is Epigenetically Regulated by BET Proteins and Inhibited by Apabetalone (RVX-208) in vitro and in CVD Patients. Abstract currently embargoed but will be available here.